Cover Image
市場調查報告書

EpiCast Report:多發性硬化症的流行病學預測

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 258690
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:多發性硬化症的流行病學預測 EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024
出版日期: 2015年09月14日 內容資訊: 英文 58 Pages
簡介

多發性硬化症(MS)在全球每年影響250萬人,是青壯年中最大的衰弱性神經疾病。調查對象10個國家整體病例數2014年估計為909,398件,至2024年預計增加到942,567件。

本報告提供多發性硬化症(MS)的風險因素及全球趨勢的相關調查,主要8個市場(美國、法國、德國、義大利、西班牙、英國、日本、加拿大)及新興市場(印度、中國)的資料。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險因素和共生病症
    • MS患者的家族持有MS發病的1%∼5%的風險
    • 女性MS發病的風險為2倍,可是男性預後不佳
    • 白種人(Caucasian)比其他人種/民族的MS風險高
    • 維他命D對MS的預防效果,可能與出生的地區、月份有關聯
    • 環境暴露的時機影響MS風險
    • 被動吸煙有可能增加MS風險,讓預後惡化
    • 自體免疫疾病可能成為MS的共生病症
    • 精神性共生病症在MS患者中最大60%,有可能影響復發率
  • 全球趨勢
    • 北美
    • 歐洲
    • 亞洲
  • 預測手法
    • 利用來源
    • 未利用的來源
    • 預測的前提條件、手法
  • 多發性硬化症的流行病學預測
    • 患病數
    • 患病數:各年齡
    • 患病數:性別
    • 發病數
    • 發病數:各年齡
    • 發病數:性別
    • 多發性硬化症的亞型
  • 考察
    • 流行病學趨勢的結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER088-15

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. The course of MS seems to be unpredictable as some people diagnosed with the condition appear to be normal and healthy for a few years after diagnosis, while others may be debilitated very quickly after diagnosis. People with MS experience a host of symptoms, which may vary with the course of the disease. The estimated prevalence and incidence of MS vary greatly between countries, within countries, and by age and sex.

In 2014, there were a total of 909,398 diagnosed prevalent cases of MS in the 10MM, and GlobalData epidemiologists forecast that by 2024, the number of diagnosed prevalent cases of MS will grow to 942,567 cases. In 2014, there were a total of 60,535 diagnosed incident cases of MS in the 10MM, and GlobalData epidemiologists forecast the number of diagnosed incident cases of MS to grow to 62,635 cases in the 10MM in 2024.

GlobalData epidemiologists forecast the diagnosed prevalent and diagnosed incident cases of MS in the 10MM from 2014-2024 using country-specific studies published in peer-reviewed journals that provided the age- and sex-specific diagnosed prevalence and diagnosed incidence of MS in the respective markets. The epidemiologists made sure that all the selected nationally-representative studies in the respective countries assessed the prevalence and incidence using the same study definition, thereby ensuring that the results forecast for each country are comparable. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

  • The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for MS in the ten major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Canada, China, and India). It includes a 10-year epidemiological forecast of the diagnosed prevalent and diagnosed incident cases of MS segmented by sex and age in these markets. This report also includes a discussion of three types of MS; relapse remitting (RRMS), primary progressive (PPMS), and secondary progressive (SPMS).
  • The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global MS market.
  • Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for MS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Family members of MS patients have a 1-5% risk of developing MS
    • 3.2.2. Women are twice as likely to develop MS, but men have a worse prognosis
    • 3.2.3. Caucasians have a higher risk of MS than any other race/ethnicity
    • 3.2.4. Protective effect of vitamin D on MS may relate to latitude and month of birth
    • 3.2.5. Timing of environmental exposures affects MS risk
    • 3.2.6. Exposure to smoking may increase MS risk and worsen prognosis
    • 3.2.7. Autoimmune diseases are comorbidities of MS
    • 3.2.8. Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates
  • 3.3. Global Trends
    • 3.3.1. North America
    • 3.3.2. Europe
    • 3.3.3. Asia
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for MS (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of MS
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of MS
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of MS
    • 3.5.4. Diagnosed Incident Cases of MS
    • 3.5.5. Age-Specific Diagnosed Incident Cases of MS
    • 3.5.6. Sex-Specific Diagnosed Incident Cases of MS
    • 3.5.7. MS Subtypes
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidites for MS
  • Table 2: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast
  • Table 3: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 4: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N (Row %), 2014
  • Table 6: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 7: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 8: 10MM, Diagnosed Incident Cases of MS, by Sex, N (Row %), 2014

List of Figures

  • Figure 1: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 2: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014
  • Figure 3: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N, 2014
  • Figure 4: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 5: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N, 2014
  • Figure 6: 10MM, Diagnosed Incident Cases of MS, by Sex, N, 2014
  • Figure 7: 10MM, MS Subtype Distributions, %*, 2014
Back to Top